文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗丙型肝炎病毒相关肝硬化患者肝细胞癌的发生率

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
PubMed 文献 · Gastroenterology · 2018-04-12

这项在意大利西西里岛22个肝脏中心开展的前瞻性研究纳入2249例接受直接抗病毒药物治疗的丙型肝炎病毒相关肝硬化患者,平均随访14个月,78例(3.5%)发生肝细胞癌;持续病毒学应答与肝细胞癌风险降低独立相关,Child-Pugh B级患者1年肝细胞癌发生率高于A级患者。

要点

  • 在平均14个月随访中,3.5%(78/2249)的丙型肝炎病毒相关肝硬化患者在接受直接抗病毒药物治疗后发生肝细胞癌。
  • 持续病毒学应答是肝细胞癌风险的独立相关因素(风险比3.40,95%置信区间1.89-6.12,P < .001,无持续病毒学应答者风险更高)。
  • Child-Pugh B级患者1年肝细胞癌发生率(有持续病毒学应答7.8%,无持续病毒学应答12.4%)高于A级患者(有持续病毒学应答2.1%,无持续病毒学应答6.6%)。

核心结论

  • 对丙型肝炎病毒相关代偿或失代偿肝硬化患者大型前瞻性研究的分析发现,直接抗病毒药物治疗获得的持续病毒学应答在平均14个月随访中降低了肝细胞癌发生率。

研究设计与样本

  • 研究为前瞻性研究,连续纳入2015年3月至2016年7月在意大利西西里岛22个学术与社区肝脏中心接受直接抗病毒药物治疗的2249例丙型肝炎病毒相关肝硬化患者,平均年龄65.4岁,男性占56.9%,Child-Pugh A级占90.5%、B级占9.5%。
  • 采用Kaplan-Meier曲线评估肝细胞癌发生,Cox回归分析识别与肝细胞癌发生相关的变量。

主要发现

  • 持续病毒学应答总率为95.2%(2140/2249),Child-Pugh A级为95.9%、B级为88.3%(P < .001)。
  • 平均随访14个月(范围6-24个月)期间,78例(3.5%)发生肝细胞癌。
  • 直接抗病毒药物暴露后1年,肝细胞癌发生率在Child-Pugh A级有持续病毒学应答者为2.1%、无持续病毒学应答者为6.6%,在Child-Pugh B级有持续病毒学应答者为7.8%、无持续病毒学应答者为12.4%(log-rank检验P < .001)。
  • 白蛋白低于3.5 g/dL(风险比1.77,95%置信区间1.12-2.82,P = .015)、血小板计数低于120 × 109/L(风险比3.89,95%置信区间2.11-7.15,P < .001)及无持续病毒学应答(风险比3.40,95%置信区间1.89-6.12,P < .001)与肝细胞癌风险升高独立相关。
  • 从直接抗病毒药物暴露至肝细胞癌诊断的平均间隔为9.8个月(范围2-22个月),有持续病毒学应答者(n=64)为9.2个月与无持续病毒学应答者(n=14)为12.0个月相比无显著差异(P = .11);有持续病毒学应答者中单个肝细胞癌病灶比例78% vs 无持续病毒学应答者50%(P = .009),病灶小于3 cm比例58% vs 28%(P = .07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. METHODS: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus-associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurrence was evaluated by Kaplan-Meier curves. Cox regression analysis was used to identify variables associated with HCC development. RESULTS: A sustained virologic response (SVR) was achieved by 2,140 patients (total = 95.2%; 95.9% with Child Pugh class A and 88.3% with Child Pugh class B; P < .001). Seventy-eight patients (3.5%) developed HCC during a mean follow-up of 14 months (range = 6-24 months). At 1 year after exposure to DAAs, HCC developed in 2.1% of patients with Child-Pugh class A with an SVR and 6.6% of patients with no SVR and in 7.8% of patients with Child-Pugh class B with an SVR and 12.4% of patients with no SVR (P < .001 by log-rank test). Albumin level below 3.5 g/dL (hazard ratio = 1.77, 95% confidence interval = 1.12-2.82, P = .015), platelet count below 120 × 109/L (hazard ratio = 3.89, 95% confidence interval = 2.11-7.15, P < .001), and absence of an SVR (hazard ratio = 3.40, 95% confidence interval = 1.89-6.12, P < .001) were independently associated increased risk for HCC. The mean interval from exposure to DAAs to an HCC diagnosis was 9.8 months (range = 2-22 months) and did not differ significantly between patients with (n = 64, 9.2 months) and without (n = 14, 12.0 months) an SVR (P = .11). A larger proportion of patients with an SVR had a single HCC lesion (78% vs 50% without an SVR; P = .009) or an HCC lesion smaller than 3 cm (58% vs 28% without an SVR; P = .07). CONCLUSIONS: In an analysis of data from a large prospective study of patients with hepatitis C virus-associated compensated or decompensated cirrhosis, we found that the SVR to DAA treatment decreased the incidence of HCC over a mean follow-up of 14 months.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018. PMID: 29655836. doi:10.1053/j.gastro.2018.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。